Wegovy is semaglutide. The active ingredient in Wegovy is the same molecule that Novo Nordisk sells under two other brand names: Ozempic for type 2 diabetes and Rybelsus as a daily oral tablet for type 2 diabetes. The differences among these products come down to FDA-approved indication, dose range, formulation, and pricing or coverage. Understanding what is the same and what is different helps you and your prescriber pick the right option for your goals and your insurance plan.
The Common Active Ingredient
Semaglutide is a 31 amino acid peptide developed by Novo Nordisk. It is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it mimics the natural gut hormone GLP-1 and binds to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract. Activation of these receptors enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. Whether you take Ozempic, Rybelsus, or Wegovy, the molecule binding the receptor is identical.
The Three Brand-Name Semaglutide Products
| Brand | Form | Frequency | FDA Indication | Max Dose |
|---|---|---|---|---|
| Ozempic | Subcutaneous injection | Once weekly | Type 2 diabetes; CV risk reduction in adults with T2D and established CVD | 2 mg |
| Rybelsus | Oral tablet | Once daily on empty stomach | Type 2 diabetes | 14 mg |
| Wegovy | Subcutaneous injection | Once weekly | Chronic weight management; CV risk reduction in adults with overweight or obesity and established CVD | 2.4 mg |
Wegovy in Detail
Wegovy was FDA-approved in June 2021 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity. In December 2022, the label expanded to include adolescents 12 years and older with obesity. In 2024, the FDA expanded the label again to include cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity. The starting dose is 0.25 mg weekly, escalated every four weeks to a maintenance dose of 2.4 mg, per the Wegovy prescribing information.
Ozempic in Detail
Ozempic was FDA-approved in 2017 for type 2 diabetes. The starting dose is 0.25 mg weekly for four weeks (a non-therapeutic initiation dose for tolerability), then 0.5 mg weekly, with possible titration to 1, 1.7, and 2 mg as needed. Per the Ozempic prescribing information, the maximum approved dose is 2 mg weekly. Ozempic is also indicated to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Rybelsus in Detail
Rybelsus is the oral semaglutide tablet, FDA-approved in 2019 for type 2 diabetes. It comes in 3, 7, and 14 mg strengths and is taken once daily on an empty stomach with no more than four ounces of plain water, then food and other medications are held for at least 30 minutes. Rybelsus is not FDA-approved for weight loss.
What Is the Same Across Wegovy, Ozempic, and Rybelsus
- Molecule: Identical semaglutide.
- Mechanism: GLP-1 receptor agonism.
- Manufacturer: Novo Nordisk.
- Boxed warning: Risk of thyroid C-cell tumors based on rodent studies.
- Common side effects: Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite.
- Serious risks: Pancreatitis, gallbladder disease, acute kidney injury, severe hypersensitivity, hypoglycemia (especially with insulin or sulfonylureas), diabetic retinopathy complications.
- Contraindications: Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
What Is Different
- Dose range: Ozempic max 2 mg; Wegovy max 2.4 mg; Rybelsus max 14 mg orally (with about 1 percent bioavailability).
- Indication: Ozempic and Rybelsus are diabetes drugs; Wegovy is a weight-management drug with cardiovascular risk reduction in non-diabetic populations with established CVD.
- Formulation: Ozempic and Wegovy are weekly subcutaneous injections; Rybelsus is a daily oral tablet.
- Insurance coverage: Ozempic for diabetes is widely covered; Wegovy for weight management has more variable coverage; Rybelsus coverage depends on the formulary tier.
- Pen design: Ozempic uses a multi-dose pen with a dial; Wegovy uses single-dose prefilled pens with a fixed strength.
What Trial Data Tells Us
The STEP-1 trial of Wegovy 2.4 mg, published in the New England Journal of Medicine, reported approximately 14.9 percent average body weight loss over 68 weeks in adults without diabetes. Trials of Ozempic 2 mg in adults with type 2 diabetes (the SUSTAIN program) generally show smaller absolute weight loss because the dose is lower and the population usually has lower starting BMI than weight-management cohorts.
Choosing the Right Semaglutide Product
For type 2 diabetes, Ozempic (or Rybelsus, if you prefer a tablet) is typically the appropriate option, with insurance coverage usually straightforward. For chronic weight management without diabetes, Wegovy is the FDA-approved choice, although coverage varies by employer and plan. If you are managing prediabetes and your clinician is considering preventive options, see our treatment hub and the overview of A1C levels for context on glucose monitoring. Off-label prescribing of Ozempic for weight loss is common but should be a transparent conversation with your prescriber about expected response and insurance implications.
Cost and Access
List prices for Wegovy and Ozempic typically exceed $1,000 per month at retail. Manufacturer savings cards (NovoCare) reduce out-of-pocket cost for eligible commercially insured patients but exclude federal program beneficiaries. The 2025 resolution of the FDA’s semaglutide shortage narrowed the legal basis for routine large-scale compounding, so non-brand sources are no longer broadly available without specific patient justification.
The Bottom Line
Wegovy and semaglutide are not different drugs. Wegovy is semaglutide, branded and dosed for chronic weight management. Ozempic and Rybelsus are also semaglutide, branded and dosed for type 2 diabetes. The molecule is the same, the safety warnings are the same, and most side effects are the same. What differs is the dose ceiling, the FDA-approved indication, the formulation, and the way insurance covers each product. Selection depends on your indication, your tolerance, and your coverage, and the choice belongs with you and your prescriber.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment plan.
